Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
89Bio Inc
(NQ:
ETNB
)
10.46
+0.50 (+5.02%)
Streaming Delayed Price
Updated: 3:54 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 89Bio Inc
< Previous
1
2
3
Next >
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
November 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the UBS Global Healthcare Conference
November 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
October 15, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
September 30, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
September 16, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
August 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Francis Sarena as Chief Operating Officer
August 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
May 22, 2024
-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
May 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
May 02, 2024
Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
April 17, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
March 27, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
March 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
February 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2023
From
89bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.